News stories about Illumina (NASDAQ:ILMN) have trended somewhat positive on Friday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Illumina earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news headlines about the life sciences company an impact score of 46.0424606065171 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- Global Genomics Market- GE Healthcare Limited, Hoffmann-La Roche, Illumina, Affymetrix , Bio-Rad Laboratories … (businessservices24.com)
- BidaskClub Upgrades Illumina (ILMN) to “Hold” (americanbankingnews.com)
- Global Single Cell Analysis Market 2018 – Corning, Qiagen, Illumina, BD Medical (marketingcorrect.com)
- KIERIN NYC – Real NYC Stories Illuminated in Fragrance (prnewswire.com)
- Illumina (ILMN) Upgraded by Vetr to Buy (americanbankingnews.com)
A number of research firms have recently weighed in on ILMN. BTIG Research reaffirmed a “hold” rating on shares of Illumina in a research note on Tuesday, January 16th. Wells Fargo raised Illumina from a “market perform” rating to an “outperform” rating and set a $205.00 price objective for the company in a research note on Tuesday, January 2nd. Evercore ISI began coverage on Illumina in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $250.00 price objective for the company. Canaccord Genuity reaffirmed a “buy” rating and issued a $265.00 price objective (up previously from $255.00) on shares of Illumina in a research note on Wednesday, January 31st. Finally, Piper Jaffray reaffirmed a “buy” rating and issued a $269.00 price objective on shares of Illumina in a research note on Tuesday, January 9th. One analyst has rated the stock with a sell rating, seven have given a hold rating and sixteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $242.08.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, January 30th. The life sciences company reported $1.44 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.22. Illumina had a return on equity of 21.71% and a net margin of 26.56%. The company had revenue of $778.00 million during the quarter, compared to analyst estimates of $752.04 million. During the same period in the prior year, the company earned $0.85 earnings per share. The firm’s revenue was up 25.7% on a year-over-year basis. equities research analysts forecast that Illumina will post 4.59 earnings per share for the current fiscal year.
In related news, Director Frances Arnold sold 250 shares of the stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $252.26, for a total transaction of $63,065.00. Following the completion of the transaction, the director now directly owns 10,189 shares of the company’s stock, valued at $2,570,277.14. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Jay T. Flatley sold 15,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $243.72, for a total value of $3,655,800.00. Following the transaction, the director now directly owns 449,201 shares of the company’s stock, valued at $109,479,267.72. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,608 shares of company stock valued at $7,936,663. 0.89% of the stock is owned by corporate insiders.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.